SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 26.06+0.3%Dec 26 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tharos who wrote (10606)7/2/1999 10:21:00 AM
From: aknahow  Read Replies (1) of 17367
 

From your area of interest. Note interest in inflammation aids.

"Kissei was founded in 1946 and has grown into one of Japan's leading pharmaceutical companies. Kissei's emphasis is
on the research and development of original drugs having the potential to be widely accepted in the world market. The
company has been successfully developing promising new drugs including those for dysuria, diabetes, and prevention
of restenosis after percutaneous transluminal coronary angioplasty (PTCA). Kissei also continues to collaborate with
Vertex on the development of VX-745, a p38 MAP kinase inhibitor for the treatment of inflammatory diseases."

From press release issued today.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext